Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies cash
Cash and short-term investments held at the end of each period.
Taysha Gene Therapies's cash was $455.41M at Jun 30, 2026. For fiscal 2025 it was $319.77M, up 130.0% from the year before. The highest annual figure on record is $319.77M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $319.77M | +130.0% |
| FY2024 | Dec 31, 2024 | $139.04M | -3.4% |
| FY2023 | Dec 31, 2023 | $143.94M | +63.8% |
| FY2022 | Dec 31, 2022 | $87.88M | -41.1% |
| FY2021 | Dec 31, 2021 | $149.10M | -40.7% |
| FY2020 | Dec 31, 2020 | $251.25M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $455.41M | +45.6% |
| Q1 FY2026 | Mar 31, 2026 | $276.58M | +137.2% |
| Q4 FY2025 | Dec 31, 2025 | $319.77M | +130.0% |
| Q3 FY2025 | Sep 30, 2025 | $297.34M | +88.6% |
| Q2 FY2025 | Jun 30, 2025 | $312.76M | +81.1% |
| Q1 FY2025 | Mar 31, 2025 | $116.59M | -6.0% |
| Q4 FY2024 | Dec 31, 2024 | $139.04M | -3.4% |
| Q3 FY2024 | Sep 30, 2024 | $157.69M | -4.0% |
| Q2 FY2024 | Jun 30, 2024 | $172.74M | +283.2% |
| Q1 FY2024 | Mar 31, 2024 | $123.98M | +95.5% |
| Q4 FY2023 | Dec 31, 2023 | $143.94M | +63.8% |
| Q3 FY2023 | Sep 30, 2023 | $164.28M | +378.9% |
| Q2 FY2023 | Jun 30, 2023 | $45.08M | -31.9% |
| Q1 FY2023 | Mar 31, 2023 | $63.43M | -34.4% |
| Q4 FY2022 | Dec 31, 2022 | $87.88M | -41.1% |
| Q3 FY2022 | Sep 30, 2022 | $34.31M | -81.8% |
| Q2 FY2022 | Jun 30, 2022 | $66.24M | -66.4% |
| Q1 FY2022 | Mar 31, 2022 | $96.63M | -57.7% |
| Q4 FY2021 | Dec 31, 2021 | $149.10M | -40.7% |
| Q3 FY2021 | Sep 30, 2021 | $188.79M | -32.2% |
| Q2 FY2021 | Jun 30, 2021 | $197.37M | – |
| Q1 FY2021 | Mar 31, 2021 | $228.68M | – |
| Q4 FY2020 | Dec 31, 2020 | $251.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $278.63M | – |
See a number that looks wrong?